Type Publicly Traded Headquarters Australia Number of locations 4 (2016) | Area served Global Founded 1999 Number of employees 60 (2016) | |
 | ||
Industry Medical Appliances & Equipment Key people Richard Carreon (CEO)
Morten Vigeland (CFO)
Jack Cosentino (CSO)
Ann Holder (SVP General Management & Operations) Products DF50
SFB7
L-Dex U400
ImpediVET
SOZO Website www.impedimed.com, www.hellosozo.com Stock price IPD (ASX) A$ 0.76 0.00 (+0.67%)10 Mar, 4:10 PM GMT+11 - Disclaimer Profiles | ||
Impedimed s two elements of blue sky
ImpediMed is an Australian medical device manufacturing company headquartered in Brisbane, Queensland. ImpediMed has offices in Carlsbad, California and Bloomington, Minnesota, as well as in Europe. The company is known primarily for its fluid status and body composition analysis devices, which utilize bioimpedance spectroscopy (BIS) technology.
Contents
A massive market opportunity for impedimed
History
ImpediMed was founded in 1999 as ImpediMed Ltd. Soon after its founding, the company worked closely with Associate Professor Leigh Ward of the University of Queensland to develop and commercialize devices incorporating bioimpedance spectroscopy (BIS) technology. The practical applications of this technology include body composition analysis and lymphedema detection.
ImpediMed launched the DF50 and SFB7, the company's first body composition monitors, in 2005. These were among the first portable devices able to use bioimpedance analysis (BIA) technology to accurately measure multiple components of body composition. The L-Dex U400, the most recent Impedimed device, uses BIS to detect lymphedema up to 10 months earlier than other methods.
In October 2007, ImpediMed Ltd. was officially listed on the Australian Stock Exchange. Shortly thereafter, ImpediMed finalized their acquirement of California-based company XITRON Technologies. With this acquisition, ImpediMed gained the ability to market their products in the United States.
After a pilot program in six US-based cancer centers, the L-Dex was commercially released in the United States in January 2016. It has since been adopted by successful hospitals and clinics; Mayo Clinic entered a clinical trial agreement with ImpediMed to explore additional possibilities for their BIS technology. In June 2016, ImpediMed announced the opening of their Minnesota office. It was then officially launched in August 2016.